Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Biome Australia Ltd ( (AU:BIO) ) has issued an announcement.
Biome Australia reported its strongest quarter on record for the three months to 31 December 2025, with sales revenue of $6.5 million, up 41% on the prior corresponding period, and rolling 12‑month revenue of about $22 million. The company delivered EBITDA of approximately $1.0 million for the quarter and $1.48 million for the first half of FY26, marking its eighth consecutive quarter of positive EBITDA, while maintaining gross margins above 61%. Cash receipts rose 43% to $6.2 million, and together with an R&D rebate, generated about $1.24 million in net operating cash inflow, enabling Biome to repay $722,000 of working capital facilities and lift its cash balance by $421,000 to $3.36 million, underscoring stronger cash generation and an improving balance sheet.
The most recent analyst rating on (AU:BIO) stock is a Hold with a A$0.46 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.
More about Biome Australia Ltd
Biome Australia Limited is a microbiome health company listed on the ASX that focuses on products targeting gut and microbiome-related wellbeing. The company generates revenue through the sale of these specialised health products, with a growing footprint reflected in rising quarterly and rolling 12‑month sales across its portfolio.
Average Trading Volume: 250,107
Technical Sentiment Signal: Sell
Current Market Cap: A$97.95M
For an in-depth examination of BIO stock, go to TipRanks’ Overview page.